Compare Stocks → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABVXNASDAQ:FIXXNASDAQ:LQDANASDAQ:SAVA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXABIVAX Société Anonyme$13.93-2.6%$14.67$7.99▼$17.02$876.62MN/A95,497 shs28,306 shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsLQDALiquidia$12.79-2.6%$13.98$5.71▼$16.99$976.90M0.24887,733 shs331,934 shsSAVACassava Sciences$21.76-1.6%$21.55$12.32▼$32.10$1.04B-0.38778,050 shs260,593 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXABIVAX Société Anonyme-0.07%+2.51%-8.86%+11.72%+1,429,999,900.00%FIXXHomology Medicines0.00%0.00%+1,700.00%+3,854.08%+3,015.67%LQDALiquidia-0.91%+6.83%-0.38%-6.48%+54.29%SAVACassava Sciences-0.67%-3.87%+7.90%-1.73%+22.35%Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXABIVAX Société Anonyme2.72 of 5 stars3.45.00.00.02.60.80.6FIXXHomology Medicines2.2641 of 5 stars3.30.00.04.80.00.80.6LQDALiquidia2.051 of 5 stars3.31.00.00.01.74.20.6SAVACassava Sciences2.9625 of 5 stars3.50.00.04.71.30.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXABIVAX Société Anonyme2.83Moderate Buy$34.20145.51% UpsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideLQDALiquidia2.60Moderate Buy$21.0064.19% UpsideSAVACassava Sciences3.00Buy$131.00502.02% UpsideCurrent Analyst RatingsLatest SAVA, ABVX, LQDA, and FIXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2024ABVXABIVAX Société AnonymeBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$43.005/17/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$124.00 ➝ $131.005/15/2024LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.005/15/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.004/29/2024ABVXABIVAX Société AnonymePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.004/29/2024ABVXABIVAX Société AnonymeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.004/11/2024ABVXABIVAX Société AnonymeMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $16.004/10/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.004/1/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/14/2024LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $32.003/13/2024LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00(Data available from 5/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXABIVAX Société AnonymeN/AN/AN/AN/AN/AN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00LQDALiquidia$17.49M55.85N/AN/A$1.13 per share11.32SAVACassava SciencesN/AN/AN/AN/A$1.64 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXABIVAX Société AnonymeN/AN/A0.00N/AN/AN/AN/AN/AN/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/ALQDALiquidia-$78.50M-$1.56N/AN/AN/A-674.42%-177.83%-78.50%8/8/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.17N/A13.35N/AN/A-66.08%-53.72%8/1/2024 (Estimated)Latest SAVA, ABVX, LQDA, and FIXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2024Q4 2023LQDALiquidia-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXABIVAX Société AnonymeN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXABIVAX Société AnonymeN/AN/AN/AFIXXHomology MedicinesN/A7.257.25LQDALiquidiaN/A7.667.50SAVACassava SciencesN/A1.741.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXABIVAX Société Anonyme47.91%FIXXHomology Medicines31.32%LQDALiquidia64.54%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipABVXABIVAX Société AnonymeN/AFIXXHomology Medicines16.10%LQDALiquidia31.60%SAVACassava Sciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABVXABIVAX Société Anonyme6162.93 millionN/ANot OptionableFIXXHomology Medicines758.13 million48.77 millionOptionableLQDALiquidia14576.38 million52.25 millionOptionableSAVACassava Sciences2947.98 million43.66 millionOptionableSAVA, ABVX, LQDA, and FIXX HeadlinesRecent News About These CompaniesMay 23 at 10:56 AM | zacks.comCassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden CrossMay 21 at 4:19 PM | bovnews.comdowngraded: B. Riley Securities Recommends Cassava Sciences Inc (NASDAQ:SAVA) Stock to “a Neutral”May 19, 2024 | americanbankingnews.comHC Wainwright Raises Cassava Sciences (NASDAQ:SAVA) Price Target to $131.00May 17, 2024 | benzinga.comPeering Into Cassava Sciences's Recent Short InterestMay 17, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Given New $131.00 Price Target at HC WainwrightMay 16, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Shares Down 6% May 15, 2024 | bovnews.comIt’s not the right time to quit: Cassava Sciences Inc (SAVA) StockMay 14, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Trading Up 9.8%May 11, 2024 | bovnews.comAnalyzing Cassava Sciences Inc’s (SAVA) Stock earnings per share and revenueMay 10, 2024 | markets.businessinsider.comSAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024May 10, 2024 | bakersfield.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of ...May 10, 2024 | msn.comCassava swings to Q1 profit as more patients finish simufilam phase 3 trialsMay 10, 2024 | msn.comCassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?May 10, 2024 | globenewswire.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamMay 10, 2024 | seekingalpha.comAnnovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's BoxMay 8, 2024 | msn.comCassava Sciences raises over $125M from warrant distributionMay 8, 2024 | globenewswire.comCassava Sciences Announces Over $125 Million Raised from Warrant DistributionMay 7, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Trading Down 6.3%May 1, 2024 | msn.comCassava Sciences files for mixed shelf offeringMay 1, 2024 | msn.com27 Best Things to Do in San Francisco, CaliforniaMay 1, 2024 | msn.comCassava: The perilous past and promising future of a toxic but nourishing cropNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsABIVAX Société AnonymeNASDAQ:ABVXABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.LiquidiaNASDAQ:LQDALiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
